Sagimet Biosciences gets FDA “Study May Proceed” letter for Phase 3
Sagimet Biosciences (SGMT) says the FDA issued a “Study May Proceed” letter and IND clearance for a Phase 3 trial in acne in adolescent and adult patients.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.